Issues related to drug supply chain and drug shortages.
Issues related to bioidentical compounded hormones.
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
H.R.3810 - Drug Origin Transparency Act of 2023.
Medicare Part D reimbursement of bulk substances.
Duration: January 15, 2020
to
present
General Issues: Health Issues , Pharmacy , Medicare/Medicaid
Spending: about $760,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2020: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jessie Brairton
Senior Legislative Asst/Legislative Asst, Rep. Lamar Smith; LC/Asst, Senate Special Aging Committee
Gary Palmquist
Legislative Director: Rep. Dennis Cardoza, Rep. Bob Clement, Rep. Ken Bentsen
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access.
Andrew Rosenberg
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $40,000. The report was filed on April 22.
Original Filing: 301575065.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages.
Issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
H.R.3810 - Drug Origin Transparency Act of 2023.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2023
In Q4, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $40,000. The report was filed on Jan. 22.
Original Filing: 301540570.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages.
Issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
H.R.3810 - Drug Origin Transparency Act of 2023.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2023
In Q3, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $40,000. The report was filed on Oct. 20, 2023.
Original Filing: 301509568.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages.
Issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2023
In Q2, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301485070.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages.
Issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2023
In Q1, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $40,000. The report was filed on April 20, 2023.
Original Filing: 301463513.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages.
Issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2022
In Q4, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $40,000. The report was filed on Jan. 20, 2023.
Original Filing: 301436371.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages.
Issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2022
In Q3, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $40,000. The report was filed on Oct. 21, 2022.
Original Filing: 301420311.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages.
Issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2022
In Q2, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301393854.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages; issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2022
In Q1, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $40,000. The report was filed on April 20, 2022.
Original Filing: 301369643.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages; issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2021
In Q4, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $50,000. The report was filed on Jan. 19, 2022.
Original Filing: 301329161.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages; issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2021
In Q3, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301314054.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages; issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2021
In Q2, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301289570.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages; issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2021
In Q1, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301262547.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages; issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2020
In Q4, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301241713.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages; issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk drug substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2020
In Q3, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301221139.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages; issues related to bioidentical compounded hormones.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk drug substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2020
In Q2, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301196731.xml
Lobbying Issues
Issues related to drug supply chain and drug shortages
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D reimbursement of bulk drug substances.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2020
In Q1, Thorn Run Partners lobbied for Professional Compounding Centers of America , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301176749.xml
Lobbying Issues
HR. 748, Coronavirus Aid, Relief and Economic Security (CARES Act); issues related to drug supply chain and drug shortages
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2020
Thorn Run Partners filed a lobbying registration on Feb. 14, 2020 to represent Professional Compounding Centers of America, effective Jan. 15, 2020.
Original Filing: 301131838.xml
Issue(s) they said they’d lobby about: Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate